内部资料、注意保密

K2LT LAB实验室
资 质 认 证 汇 编

通過基因疗法治疗與衰老相关的疾病

目 录

BA20250026110

B3320-2880 01/04/2025 2:31 PM Received by California Secretary of State

STATE OF CALIFORNIA
Office of the Secretary of State
STATEMENT OF INFORMATION
LIMITED LIABILITY COMPANY

California Secretary of State
1500 11th Street
Sacramento, California 95814
(916) 657-5448

For Office Use Only

-FILED-

File No.: BA20250026110
Date Filed: 1/4/2025

Entity Details

Limited Liability Company Name	K2LT LAB, LLC
Entity No.	202359613334
Formed In	CALIFORNIA

Street Address of Principal Office of LLC

Principal Address	170 E ARROW HWY SAN DIMAS, CA 91773

Mailing Address of LLC

Mailing Address	170 E ARROW HWY SAN DIMAS, CA 91773
Attention	

Street Address of California Office of LLC

Street Address of California Office	None

Manager(s) or Member(s)

Manager or Member Name	Manager or Member Address
■ XIANGHAI KONG	170 E ARROW HWY SAN DIMAS, CA 91773

Agent for Service of Process

Agent Name	XIANGHAI KONG
Agent Address	170 E ARROW HWY SAN DIMAS, CA 91773

Type of Business

Type of Business	BIOTECHNOLOGY RESEARCH AND DEVELOPMENT

Email Notifications

Opt-in Email Notifications	No, I do NOT want to receive entity notifications via email. I prefer notifications by USPS mail.

Chief Executive Officer (CEO)

CEO Name	CEO Address
■ XIANGHAI KONG	170 E ARROW HWY SAN DIMAS, CA 91773

Labor Judgment

No Manager or Member, as further defined by California Corporations Code section 17702.09(a)(8), has an outstanding final judgment issued by the Division of Labor Standards Enforcement or a court of law, for which no appeal is pending, for the violation of any wage order or provision of the Labor Code.

Electronic Signature

☒ By signing, I affirm under penalty of perjury that the information herein is true and correct and that I am authorized by California law to sign.

XIANGHAI KONG	*01/04/2025*
Signature	Date

FDA | Drug Firm Registration & NDC Listing
Fiscal Year 2025

This certifies that:

K2LT Lab, LLC	
170 E Arrow Hwy, San Dimas, california (cA) 91773. United States (USA)	
NDC Code	**84429**
Duns Number	**07-218-9878**
Establishment FEI	**3031259553**

#	NDC Listing#		
#	**Proprietary Name**	**NDC Package Code**	**Package Description**
1	K2LTS Telomerase Inhibitor	84429-003-01	60 mL in 1 BOX

Note: The annual registration renewal period is October 1- December 31

Was registered with U.S. FOOD & Drug Administration Center of Devices and Radiological Health pursuant to the Code of Federal Regulations 21 CFR 207. Such registration has been verified with the registrant's authorization by Andrew

查询网址(web)：
Product Registration Enquiry:
https://www.accessdata.fda.gov/scripts/cder/ndc/index.cfm
Corporate Registration Enquiry:
https://www.accessdata.fda.gov/scripts/cder/drls/default.cfm

Andrew /Chief engineer
Issued: 01/01/2025
Expiration Date: 12/31/2025

Web: http://www.fda.gov
Tel: 1-888-INFO-FDA (1-888-463-6332)
e-mail: webmail@oc.fda.gov

FDA | Drug Firm Registration & NDC Listing

Fiscal Year 2025

This certifies that:

K2LT Lab, LLC	
170 E Arrow Hwy, San Dimas, california (cA) 91773. United States (USA)	
NDC Code	**84429**
Duns Number	**07-218-9878**
Establishment FEI	**3031259553**

#	NDC Listing#		
#	**Proprietary Name**	**NDC Package Code**	**Package Description**
1	K2LTS Brain Rehabilitation	84429-004-01	60 mL in 1 BOX

Note: The annual registration renewal period is October 1- December 31

Was registered with U.S. FOOD & Drug Administration Center of Devices and Radiological Health pursuant to the Code of Federal Regulations 21 CFR 207. Such registration has been verified with the registrant's authorization by Andrew

查询网址(web)：

Product Registration Enquiry:

https://www.accessdata.fda.gov/scripts/cder/ndc/index.cfm

Corporate Registration Enquiry:

https://www.accessdata.fda.gov/scripts/cder/drls/default.cfm

Andrew

Shenzhen CIIC Testing Service Co.,Ltd. CIIC Approved

Andrew /Chief engineer

Issued: 01/01/2025

Expiration Date: 12/31/2025

Web: http://www.fda.gov

Tel: 1-888-INFO-FDA (1-888-463-6332)

e-mail: webmail@oc.fda.gov

FDA FFR | FOOD FACILITY REGISTRATION

Fiscal Year 2026

This certifies that:

K2LT Lab, LLC

170 E Arrow Hwy, San Dimas, california (cA) 91773. United States (USA)

Is registered with the U.S. Food and Drug Administration pursuant to section 305 of the United States Public Health Security and Bio terrorism Preparedness and Response Act of 2002, PL.107-188, such registration having been verified as currently effective on the date here of by Rizhao Dayee Certification Co., Ltd

U.S.FDA Registration No. :	**15691898176**
D-U-N-S Number :	**07-218-9878**
Product name :	● **K2LTS Telomerase Inhibitor**
	● **K2LTS Brain Rhabilitation**

This certificate affirms that the above stated facility is registered with the U.S. Food and Drug Administration pursuant to section 305 of the U.S. Public Health Security and Bioterrorism Preparedness and Response Act of 2002, P.L. 107-188, such registration having been verified as effective by Rizhao Dayee Certification Co., Ltd as of the date hereof, and Rizhao Dayee Certification Co., Ltd will confirm that such registration remains effective upon request and presentation of this certificate until the expiration of one year from the date hereof, unless terminated after issuance of this certificate. Rizhao Dayee Certification Co., Ltd makes no other presentations or warranties, nor does this certificate make any representations or warranties to any person or entity other than the named certificate holder, for whose sole benefit it is issued. Rizhao Dayee Certification Co., Ltd assume no liability to any person or entity in connection with the foregoing. The U.S. Food and Drug Administration does not issue a certificate of registration, nor does the U.S. Food and Drug Administration recognize a certificate of registration. Rizhao Dayee Certification Co., Ltd is not affiliated with the U.S. Food and Drug Administration.

Shenzhen CIIC Testing Service Co., Ltd. CIIC Approved

Web: http://www.fda.gov
Tel: 1-888-INFO-FDA (1-888-463-6332)
e-mail: webmail@oc.fda.gov

Andrew /Chief engineer
Issued: 12/11/2024
Expiration Date: 12/31/2026

Certificate

OF FDA REGISTRATION 2024

This is to certify that.

[redacted]

Is registered with the U.S. Food and Drug Administration pursuant to U.S. Code of Federal Regulations 21 CFR Part 1, Subpart H, and the Public Health Security and Bioterrorism Preparedness and Response Act of 2002. This registration is being verified as valid by MettiFDA Corporation

U.S. FDA Food Facility Registration Number: 19957517730
Registration Date: 11/15/2023
Expiration Date: 12/31/2024
D.U.N.S : 052115351
FDA Product Category: Food
Official FDA U.S. Agent: MettiFDA Corporation - USID5431868

This certificate confirms that the above -mentioned establishment is registered with the FDA on the date stated above and will remain effective until the expiration date. This certificate has only been issued for the confirmation of such registration and does not constitute as the FDA product approval. MettiFDA Corporation is a private registration agent and has no affiliation with the United States Food and Drug Administration.

Metti FDA
FDA U.S. Agent: USID5431868
9191 Bolsa ave Unit 210
Westminster, CA 92683
www.mettifda.co
info@mettifda.co

Certificate Issue date
11/15/2023

Prof.Nicholas Phan, DBA
President

CENTERS FOR MEDICARE & MEDICAID SERVICES

CLINICAL LABORATORY IMPROVEMENT AMENDMENTS

CERTIFICATE OF REGISTRATION

LABORATORY NAME AND ADDRESS

[redacted]

CLIA ID NUMBER

05D2258468

EFFECTIVE DATE

04/21/2022

LABORATORY DIRECTOR

WENHUI L LI Ph.D.

EXPIRATION DATE

04/20/2024

Pursuant to Section 353 of the Public Health Services Act (42 U.S.C. 263a) as revised by the Clinical Laboratory Improvement Amendments (CLIA), the above named laboratory located at the address shown hereon (and other approved locations) may accept human specimens for the purposes of performing laboratory examinations or procedures.

This certificate shall be valid until the expiration date above, but is subject to revocation, suspension, limitation, or other sanctions for violation of the Act or the regulations promulgated thereunder.

CMS
CENTERS FOR MEDICARE & MEDICAID SERVICES

Monique Spruill

Monique Spruill, Director
Division of Clinical Laboratory Improvement & Quality
Quality & Safety Oversight Group
Center for Clinical Standards and Quality

2710 Certs1_051722

- If this is a Certificate of Registration, it represents only the enrollment of the laboratory in the CLIA program and does not indicate a Federal certification of compliance with other CLIA requirements. The laboratory is permitted to begin testing upon receipt of this certificate, but is not determined to be in compliance until a survey is successfully completed.
- If this is a Certificate for Provider-Performed Microscopy Procedures, it certifies the laboratory to perform only those laboratory procedures that have been specified as provider-performed microscopy procedures and, if applicable, examinations or procedures that have been approved as waived tests by the Department of Health and Human Services.
- If this is a Certificate of Waiver, it certifies the laboratory to perform only examinations or procedures that have been approved as waived tests by the Department of Health and Human Services.

FOR MORE INFORMATION ABOUT CLIA, VISIT OUR WEBSITE AT WWW.CMS.GOV/CLIA
OR CONTACT YOUR LOCAL STATE AGENCY. PLEASE SEE THE REVERSE FOR
YOUR STATE AGENCY'S ADDRESS AND PHONE NUMBER.
PLEASE CONTACT YOUR STATE AGENCY FOR ANY CHANGES TO YOUR CURRENT CERTIFICATE.

CLINICAL AND PUBLIC HEALTH LABORATORY LICENSE

In accordance with the provisions of Chapter 3, Division 2 of the Business and Professions Code, the persons named below are hereby issued a license authorizing operation of a clinical laboratory at the indicated address.

[redacted]

STATE ID: CLR-90014650

SCAN QR CODE TO VERIFY LICENSE
OR VISIT: www.cdph.ca.gov/LFS

EFFECTIVE DATE: 01/24/2025

EXPIRATION DATE: 01/24/2026

LICENSE TYPE:
CLINICAL LABORATORY REGISTRATION

OWNER/S:
ZHENG, XIAOYAN

DIRECTOR/S:
THOMAS TUAN TON LEE, MD

DISPLAY: State law requires that the clinical laboratory license shall be conspicuously posted in the clinical laboratory.

CHANGE OF LABORATORY NAME, DIRECTOR, OWNER AND/OR ADDRESS:
State law requires that the laboratory owner and/or the director notify this office within 30 days of any change in ownership, name, location, or laboratory directors.
If this office is not notified, your license may be revoked 30 days after major Owner and/or Director change.
If your license is revoked, you must cease engaging in clinical laboratory practice and apply for a new laboratory license.
To make these changes or to submit a new application, visit our website: https://www.cdph.ca.gov/LFS *(Go to Laboratory Facilities)*

Robert J. Thomas

ROBERT J. THOMAS
BRANCH CHIEF
LABORATORY FIELD SERVICES

LAB CERT 300 (02-2022)

cGMP/ ORIGIN STATEMENT

K2LT LAB, LLC is regulated by the Food and Drug Administration (FDA) pursuant to the requirements of the Federal Food, Drug, and Cosmetic Act (FD & C Act) and the fair packaging act (FPLA), and other related federal and state laws.

The above-named facility and controls used for the manufacturing and distribution of K2LT LAB, LLC products conform with Current Good Manufacturing Practices, in accordance with Section 211, Title 21, Code of Federal Regulations and the Federal Drug and Cosmetic Act, and the Amend-

We certify the above statements to be accurate and correct to the best of our knowledge and belief.

K2LT LAB, LLC

AMERICAN WORLD TRADE CHAMBER OF COMMERCE
CERTIFIED FILED
07 May 2024
Brenda Howley
USA

Willing Tiger

Valid From: 04/2024
Valid Until: 04/2026

OD-24-119426-01

The Global Language of Business

GS1 Company Prefix Certificate

Licensed to:

K2LT LAB, LLC

"Licensee"

GS1 Company Prefix: **08600116520**

Original Issue Date: **01/30/2024**

U.P.C. Company Prefix: **8600116520**

Legal Entity Global Location Number (GLN): **0860011652007**

To continue the use of this prefix, your license must be renewed on or before: **01/31/2026**

Account Number: **30229236**

GS1 US
Princeton South Corporate Center
300 Charles Ewing Boulevard
Ewing, NJ 08628 USA

T +1 937.435.3870
E info@gs1us.org
www.gs1us.org

For information regarding your subscription and license agreement, visit **www.gs1us.org/subscription**

Bob Carpenter
President and CEO, GS1 US

The GS1 Company Prefix and the corresponding U.P.C. Company Prefix ("the Prefixes") are licensed for the sole and exclusive use of the licensee and are restricted to the member to whom they are licensed. Only one company may use the Prefixes. Any other use of the Prefixes is prohibited, including but not limited to renting, leasing or subdividing all or portion of the Prefixes. Upon the sale of a company, division, or product line, Licensee shall forward a letter signed by both parties to the transaction or a copy of the legal agreement to evidence that the Prefixes were part of such sale before GS1 US® may, in its sole discretion, change its official registration for any Prefixes involved in the sale.

统一社会信用代码
91460000MAD6RLM00K

营业执照

（副 本）（ 1-1 ）

扫描二维码登录'国家企业信用信息公示系统'了解更多登记、备案、许可、监管信息。

名　　称　乔戈里峰进出口贸易（海南）有限公司

类　　型　有限责任公司（非自然人投资或控股的法人独资）

法定代表人　李振东

经营范围　许可项目：互联网信息服务；酒类经营；食品互联网销售（依法须经批准的项目，经相关部门批准后方可开展经营活动）
一般项目：食品销售（仅销售预包装食品）；保健食品（预包装）销售；食品互联网销售（仅销售预包装食品）；第一类医疗器械销售；第二类医疗器械销售；健康咨询服务（不含诊疗服务）；电子元器件批发；电子元器件零售；电子产品销售；服装服饰批发；服装服饰零售；服装辅料销售；国内贸易代理；日用品销售；互联网销售（除销售需要许可的商品）；日用杂品销售；食品销售（仅销售预包装食品，不含酒）；生物基材料技术研发；生物基材料销售；化工产品销售（不含许可类化工产品）；生物化工产品技术研发；技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；日用化学产品销售（除许可业务外，可自主依法经营法律法规非禁止或限制的项目）

注册资本　贰佰万圆整

成立日期　2023年11月29日

住　　所　海南省琼海市中原镇博鳌乐城医疗旅游先行区乐天路号药械展A101-105

登记机关　海南省市场监督管理局 登记专用章

2023 年 11 月 29 日

琼 03199729

国家企业信用信息公示系统网址：http://www.gsxt.gov.cn

市场主体应当于每年1月1日至6月30日通过国家企业信用信息公示系统报送公示年度报告

国家市场监督管理总局监制

报关单位备案证明

统一社会信用代码	91460000MAD6RLM00K
名称	乔戈里峰进出口贸易（海南）有限公司
所在地海关	博鳌机场海关
经营类别	进出口货物收发货人
证明出具时间	2024 年 06 月 27 日

说明：1. 本备案证明自出具之日并加盖海关印章后一日内有效。

2. 可以通过“中国海关企业进出口信用信息公示平台”查询报关单位备案情况。（网址：http://credit.customs.gov.cn）

互联网药品信息服务资格备案表

备案序号：（琼）网药信服务备字〔2024〕第0026号

单位名称	乔戈里峰进出口贸易（海南）有限公司
单位地址	海南省琼海市中原镇博鳌乐城医疗旅游先行区乐天路号药械展　A101－105
单位邮编	571400
法定代表人	李振东
网站负责人	曾金菊
网站名称	乔戈里峰进出口贸易（海南）有限公司
服务器所在地地址	北京市朝阳区酒仙桥东路　1　号　M3　楼
网站域名	k2ltlab.cn
网站 IP 地址	123.56.161.145
服务性质	经营性
备案编号	（琼）—经营性—2024—0012

备案部门（公章）：海南省药品监督管理局

备案日期：2024年03月25日

有效期至：2029年03月24日

中华人民共和国
增值电信业务经营许可证

经营许可证编号：琼B2-20240484

根据《中华人民共和国电信条例》及国家有关规定，经审查，准许你公司按照本经营许可证（正文和附件）载明的内容经营增值电信业务，特颁发增值电信业务经营许可证。

公司名称：乔戈里峰进出口贸易（海南）有限公司

法定代表人：李振东

业务种类（服务项目）及覆盖范围：在线数据处理与交易处理业务(仅限经营类电子商务)
不含网络借贷信息中介类的互联网金融业务。【依法须经批准的项目，经相关部门批准后方可开展相应经营活动】

信息服务业务（仅限互联网信息服务）
不含信息搜索查询服务、信息即时交互服务。【依法须经批准的项目，经相关部门批准后方可开展相应经营活动】

发证机关(盖章)：

发证日期：2024年06月06日

有效期至：2029年06月06日

治疗阿尔茨海默症的蛋白组合物的医疗应用

Medical application of protein compositions for the treatment of Alzheimer's disease

专利号：63599683

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
63/559,683	02/29/2024		60	JZ24-SFP38		

CONFIRMATION NO. 4982

FILING RECEIPT

122312
Law Offices of James Zhou
17700 Castleton Street, Ste 568
City of Industry, CA 91748

OC0000000070952401*

Date Mailed: 04/11/2024

Receipt is acknowledged of this provisional patent application. It will not be examined for patentability and will become abandoned not later than twelve months after its filing date. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF FIRST INVENTOR, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection.

Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a corrected Filing Receipt identifying the requested changes, preferably by including a properly marked-up ADS showing the changes with strike-through for deletions and underlining for additions. If you received a "Notice to File Missing Parts" or other Notice requiring a response for this application, please submit any request for correction to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections provided that the request is grantable.

Inventor(s)

XIANGHAI KONG, SAN GABRIEL, CA;

Applicant(s)

K2LT LAB, LLC, SAN GABRIEL, CA;

Power of Attorney:
JIANMIN ZHOU -68421

Permission to Access Application via Priority Document Exchange: Yes

Permission to Access Search Results: Yes

Applicant may provide or rescind an authorization for access using Form PTO/SB/39 or Form PTO/SB/69 as appropriate.

If Required, Foreign Filing License Granted: 04/10/2024

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 63/559,683**

Projected Publication Date: None, application is not eligible for pre-grant publication

Non-Publication Request: No

Early Publication Request: No

**** MICRO ENTITY ****

Title

MEDICAL APPLICATION OF A PROTEIN COMPOSITION FOR TREATING ALZHEIMER'S DISEASE

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4258).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as

set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to promote and facilitate business investment. SelectUSA provides information assistance to the international investor community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states, and regions competing for global investment; and counsels U.S. economic development organizations on investment attraction best practices. To learn more about why the United States is the best country in the world to develop technology, manufacture products, deliver services, and grow your business, visit http://www.SelectUSA.gov or call +1-202-482-6800.

端粒酶抑制剂治疗癌症的医疗应用

Application of telomerase inhibitors in the treatment of cancer

专利号：63599664

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
63/559,664	02/29/2024		60	JZ24-SFP37		

CONFIRMATION NO. 9684

FILING RECEIPT

OC000000069260857

122312
Law Offices of James Zhou
17700 Castleton Street, Ste 568
City of Industry, CA 91748

Date Mailed: 03/07/2024

Receipt is acknowledged of this provisional patent application. It will not be examined for patentability and will become abandoned not later than twelve months after its filing date. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF FIRST INVENTOR, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection.

Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a corrected Filing Receipt identifying the requested changes, preferably by including a properly marked-up ADS showing the changes with strike-through for deletions and underlining for additions. If you received a "Notice to File Missing Parts" or other Notice requiring a response for this application, please submit any request for correction to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections provided that the request is grantable.

Inventor(s)

XIANGHAI KONG, SAN GABRIEL, CA;

Applicant(s)

K2LT LAB, LLC, SAN GABRIEL, CA;

Power of Attorney:
JIANMIN ZHOU -68421

Permission to Access Application via Priority Document Exchange: Yes

Permission to Access Search Results: Yes

Applicant may provide or rescind an authorization for access using Form PTO/SB/39 or Form PTO/SB/69 as appropriate.

If Required, Foreign Filing License Granted: 03/06/2024

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 63/559,664**

Projected Publication Date: None, application is not eligible for pre-grant publication

Non-Publication Request: No

Early Publication Request: No

** **MICRO ENTITY** **

Title

APPLICATION OF TELOMERASE INHIBITOR

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4258).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier

license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to promote and facilitate business investment. SelectUSA provides information assistance to the international investor community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states, and regions competing for global investment; and counsels U.S. economic development organizations on investment attraction best practices. To learn more about why the United States is the best country in the world to develop technology, manufacture products, deliver services, and grow your business, visit http://www.SelectUSA.gov or call +1-202-482-6800.

NADH离子包裹技术医疗应用

Medical applications of NADH ion encapsulation technology

专利号：6382542 7

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
63/825,427	06/17/2025		65	JZ25-SFP48		

CONFIRMATION NO. 5943

FILING RECEIPT

OC00000091339965

122312
Law Offices of James Zhou
17700 Castleton Street, Ste 568
City of Industry, CA 91748

Date Mailed: 07/11/2025

Receipt is acknowledged of this provisional patent application. It will not be examined for patentability and will become abandoned not later than twelve months after its filing date. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF FIRST INVENTOR, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection.

Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a corrected Filing Receipt identifying the requested changes, preferably by including a properly marked-up ADS showing the changes with strike-through for deletions and underlining for additions. If you received a "Notice to File Missing Parts" or other Notice requiring a response for this application, please submit any request for correction to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections provided that the request is grantable.

Inventor(s)

XIANGHAI KONG, SAN DIMAS, CA;

Applicant(s)

K2LT BIOTECH INC, SAN DIMAS, CA;

Power of Attorney:
JIANMIN ZHOU -68421

Permission to Access Application via Priority Document Exchange: Yes

Permission to Access Search Results: Yes

Applicant may provide or rescind an authorization for access using Form PTO/SB/39 or Form PTO/SB/69 as appropriate.

If Required, Foreign Filing License Granted: 07/10/2025

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 63/825,427**

Projected Publication Date: None

Non-Publication Request: No

Early Publication Request: No

**** MICRO ENTITY ****

Title

MEDICAL APPLICATION OF NADH ION ENCAPSULATION TECHNOLOGY

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4258).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier

license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to promote and facilitate business investment. SelectUSA provides information assistance to the international investor community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states, and regions competing for global investment; and counsels U.S. economic development organizations on investment attraction best practices. To learn more about why the United States is the best country in the world to develop technology, manufacture products, deliver services, and grow your business, visit http://www.SelectUSA.gov or call +1-202-482-6800.

Welcome to the U.S. Patent and Trademark Office (USPTO)

*Congratulations on taking the first step to protect your invention. You can now advertise or mark any products covered by this application for your invention as **"Patent Pending"** for as long as this application is pending!*

We are here to help you on the rest of your journey.

New to the process? The Patent Basics page will take you from "What is a patent?" to assistance with the application process.

- **www.uspto.gov/PatentBasics**

Consider cost savings. You might qualify for small entity or micro entity status, which means a discount on most USPTO patent fees.

- **www.uspto.gov/EntityStatus**

Become a registered electronic filer (eFiler). You'll gain access to the full capabilities of Patent Center. As a registered eFiler, you can electronically view your submission, track the progress of your application, and respond to USPTO correspondence.

- **www.uspto.gov/NewPatentFilers**

Learn how to identify which of your creative ideas might be intellectual property assets and how to protect them by using the USPTO Intellectual Property (IP) Identifier.

- **ipidentifier.uspto.gov**

We also provide Pro Se Assistance, support specifically geared for independent inventors without an attorney or agent. Follow the link below, call us at 866-767-3848, or email proseassistancecenter@uspto.gov.

- **www.uspto.gov/ProSePatents**

Need help near you? We have regional offices across the country, as well as Patent and Trademark Resource Centers in libraries in nearly every state, with specialists standing by to help you at no cost.

- **www.uspto.gov/locations**
- **www.uspto.gov/ptrc**

Contact us:

- General information: USPTO Contact Center
  - **www.uspto.gov/help**
- Patent Center:
  Patent Electronic Business Center
  - **www.uspto.gov/EBC**
- Pre or post-examination: Application Assistance Unit
  - **www.uspto.gov/PatentAssistance**

Want to learn more?

- Access our free services all in one spot. Find all of our contact centers, nationwide services, events, education, and training.
  - **www.uspto.gov/FreeServices**
- Connect with us on Instagram, LinkedIn, Twitter, Facebook, and YouTube.
- Hear about resources for startups, inventors, and entrepreneurs, as well as our initiatives engaging women, the military community, and others. These programs offer helpful tips and tricks on identifying and managing your IP, finding options for funding, and expanding your network to support your business.
  - **www.uspto.gov/startups**
  - **www.uspto.gov/inventors**
  - **www.uspto.gov/initiatives**
- We hope you connect with us by subscribing to receive important notifications by email.
  - **www.uspto.gov/subscribe**

uspto UNITED STATES PATENT AND TRADEMARK OFFICE ®

THANK YOU

来自美利坚尖端科技